Reporting rates for glandular neoplasia in 464,754 cervical samples reported at six laboratories in 12-month periods before and after the implementation of Surepath™ LBC processing are compared. The introduction of LBC processing is seen to have resulted in a significant (P = 0.001) increase in the detection rate for endocervical glandular neoplasia (from 2.2 per 10,000 tests to 3.9 per 10,000) while maintaining high levels of reporting specificity. An observed fall in the number of samples reported as showing borderline glandular neoplasia falls short of statistical significance, and the reporting of possible endometrial and 'other' glandular abnormalities appears to be unaffected. The underlying reasons for the observed improvement in detection of endocervical glandular neoplasia are discussed.

This study was undertaken by a pathology network providing cervical cytology screening services across two trusts, using SurePath LBC technology. The aim of this study was to establish if LBC screening results and histological correlation was in concordance with the pilot sites findings, with particular reference to glandular atypia. All the data was extrapolated from the Apex database for the specified times using Cognos. Data from Jan to Dec 2004 (last complete year conventional cytology) and Jan to Dec 2006 (first complete year LBC) have been used in this study. In summary from 2004 to 2006 we found:  A reduction in the inadequate rate to 1.1%  Low‐grade rates remained stable 4.9%  High grade grades increased by 45% (PPV 84%)  Glandular neoplasia increased by 75% with a PPV for endocervical origin of 92% and for endometrial cell origin of 43%  Borderline endocervical rates remained stable 0.036% (PPV 50%) The PPV of endometrial glandular neoplasia was disappointing and possibly reflects increased endometrial sampling, reduced adherence to mid‐cycle sampling, and our lack of experience, resulting in poor endometrial interpretation. In conclusion, our data produced a different profile to the pilot sites with increase high grade and ? Glandular neoplasia reporting, but with a significant overcall in endometrial glandular neoplasia.

No abstract